Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018

Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar
Disorder Drug Market to Decline By More Than $1 Billion Through 2018
Beginning in 2011, Key Agents from AstraZeneca, Eli Lilly, Pfizer and
Bristol-Myers Squibb/Otsuka Will Lose Patent Exclusivity, According to a New
Report from Decision Resources

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources, one of the world's
leading research and advisory firms for pharmaceutical and healthcare issues,
finds that widespread generic erosion of branded atypical antipsychotics will
cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to
approximately $5 billion in 2018 in the United States, France, Germany, Italy,
Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Bipolar Disorder finds that the market will
be constrained over the next several years by the patent expiries and
subsequent generic erosion of key antipsychotic agents such as AstraZeneca's
Seroquel, Eli Lilly's Zyprexa, Bristol-Myers Squibb/Otsuka's Abilify and
Pfizer's Geodon. In 2008, sales of atypical antipsychotics exceeded $4 billion
but generic competition, beginning in 2011, will cause sales of these agents
to decline to just under $3 billion by 2018, according to the report.
Additionally, patent expiries of branded antidepressants that include Wyeth's
(now Pfizer's) Effexor XR, Eli Lilly's Cymbalta/Xeristar and Forest/Lundbeck's
Lexapro/Cipralex will further constrain the market.

"Despite the overall decline in the market, we forecast that sales for bipolar
disorder therapies in Europe and Japan will grow modestly from 2008 to 2018,"
said Decision Resources Analyst Alana Simorellis, Ph.D. "Market growth in
Europe and Japan will be due in part to the continued uptake of atypical
antipsychotics and an increasing drug-treated population for the indication."

The report also finds that the expanded labeling for AstraZeneca's
Seroquel/Seroquel XR to include bipolar maintenance and bipolar depression as
well as the potential approval of Dainippon Sumitomo's lurasidone for bipolar
depression, will serve to differentiate these therapies from other atypical
antipsychotics. Experts indicate that bipolar depression is difficult to
treat, and there is substantial market opportunity for therapies that address
this market segment.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

Decision Resources
Christopher Comfort
781-296-2597
ccomfort@dresources.com

Decision Resources, Inc.
Elizabeth Marshall
781-296-2563
emarshall@dresources.com

SOURCE Decision Resources

Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com